|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAGEF1 |
Gene summary for MAGEF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAGEF1 | Gene ID | 64110 |
| Gene name | MAGE family member F1 | |
| Gene Alias | MAGE-F1 | |
| Cytomap | 3q27.1 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | Q9HAY2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64110 | MAGEF1 | GSM4909281 | Human | Breast | IDC | 7.04e-34 | 6.26e-01 | 0.21 |
| 64110 | MAGEF1 | GSM4909285 | Human | Breast | IDC | 2.13e-26 | 4.93e-01 | 0.21 |
| 64110 | MAGEF1 | GSM4909286 | Human | Breast | IDC | 1.28e-14 | 3.29e-01 | 0.1081 |
| 64110 | MAGEF1 | GSM4909293 | Human | Breast | IDC | 2.88e-06 | 2.43e-01 | 0.1581 |
| 64110 | MAGEF1 | GSM4909297 | Human | Breast | IDC | 2.91e-02 | 4.42e-02 | 0.1517 |
| 64110 | MAGEF1 | GSM4909298 | Human | Breast | IDC | 7.20e-06 | 1.93e-01 | 0.1551 |
| 64110 | MAGEF1 | GSM4909308 | Human | Breast | IDC | 7.15e-05 | 2.52e-01 | 0.158 |
| 64110 | MAGEF1 | GSM4909311 | Human | Breast | IDC | 5.34e-04 | -1.03e-01 | 0.1534 |
| 64110 | MAGEF1 | GSM4909318 | Human | Breast | IDC | 1.75e-02 | 3.15e-01 | 0.2031 |
| 64110 | MAGEF1 | GSM4909319 | Human | Breast | IDC | 7.72e-09 | -1.33e-01 | 0.1563 |
| 64110 | MAGEF1 | brca1 | Human | Breast | Precancer | 4.73e-02 | 1.45e-01 | -0.0338 |
| 64110 | MAGEF1 | brca2 | Human | Breast | Precancer | 1.27e-07 | 2.18e-01 | -0.024 |
| 64110 | MAGEF1 | brca3 | Human | Breast | Precancer | 4.44e-02 | 1.49e-01 | -0.0263 |
| 64110 | MAGEF1 | M2 | Human | Breast | IDC | 3.17e-03 | 2.42e-01 | 0.21 |
| 64110 | MAGEF1 | NCCBC14 | Human | Breast | DCIS | 3.77e-03 | 9.09e-02 | 0.2021 |
| 64110 | MAGEF1 | P1 | Human | Breast | IDC | 2.54e-04 | -1.22e-01 | 0.1527 |
| 64110 | MAGEF1 | P2 | Human | Breast | IDC | 3.51e-05 | 3.63e-01 | 0.21 |
| 64110 | MAGEF1 | DCIS2 | Human | Breast | DCIS | 3.77e-38 | 7.46e-02 | 0.0085 |
| 64110 | MAGEF1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.15e-04 | 1.40e-01 | 0.0155 |
| 64110 | MAGEF1 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.92e-05 | 2.02e-01 | -0.1088 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00458629 | Breast | Precancer | positive regulation of proteolysis | 51/1080 | 372/18723 | 7.77e-09 | 5.70e-07 | 51 |
| GO:19033629 | Breast | Precancer | regulation of cellular protein catabolic process | 36/1080 | 255/18723 | 6.03e-07 | 2.55e-05 | 36 |
| GO:00421769 | Breast | Precancer | regulation of protein catabolic process | 47/1080 | 391/18723 | 1.50e-06 | 5.58e-05 | 47 |
| GO:19030509 | Breast | Precancer | regulation of proteolysis involved in cellular protein catabolic process | 31/1080 | 221/18723 | 4.10e-06 | 1.27e-04 | 31 |
| GO:00098969 | Breast | Precancer | positive regulation of catabolic process | 48/1080 | 492/18723 | 2.62e-04 | 3.84e-03 | 48 |
| GO:00313319 | Breast | Precancer | positive regulation of cellular catabolic process | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
| GO:20000589 | Breast | Precancer | regulation of ubiquitin-dependent protein catabolic process | 21/1080 | 164/18723 | 5.00e-04 | 6.53e-03 | 21 |
| GO:19033649 | Breast | Precancer | positive regulation of cellular protein catabolic process | 20/1080 | 155/18723 | 6.10e-04 | 7.67e-03 | 20 |
| GO:19030527 | Breast | Precancer | positive regulation of proteolysis involved in cellular protein catabolic process | 17/1080 | 133/18723 | 1.68e-03 | 1.70e-02 | 17 |
| GO:00457329 | Breast | Precancer | positive regulation of protein catabolic process | 25/1080 | 231/18723 | 1.87e-03 | 1.82e-02 | 25 |
| GO:20010208 | Breast | Precancer | regulation of response to DNA damage stimulus | 24/1080 | 219/18723 | 1.93e-03 | 1.87e-02 | 24 |
| GO:00516047 | Breast | Precancer | protein maturation | 28/1080 | 294/18723 | 6.45e-03 | 4.50e-02 | 28 |
| GO:004586214 | Breast | IDC | positive regulation of proteolysis | 66/1434 | 372/18723 | 9.76e-11 | 1.29e-08 | 66 |
| GO:004217614 | Breast | IDC | regulation of protein catabolic process | 63/1434 | 391/18723 | 1.32e-08 | 9.61e-07 | 63 |
| GO:190336214 | Breast | IDC | regulation of cellular protein catabolic process | 46/1434 | 255/18723 | 4.00e-08 | 2.68e-06 | 46 |
| GO:190305014 | Breast | IDC | regulation of proteolysis involved in cellular protein catabolic process | 41/1434 | 221/18723 | 9.77e-08 | 5.84e-06 | 41 |
| GO:190336414 | Breast | IDC | positive regulation of cellular protein catabolic process | 29/1434 | 155/18723 | 5.93e-06 | 1.90e-04 | 29 |
| GO:200005814 | Breast | IDC | regulation of ubiquitin-dependent protein catabolic process | 30/1434 | 164/18723 | 6.62e-06 | 2.05e-04 | 30 |
| GO:004573214 | Breast | IDC | positive regulation of protein catabolic process | 37/1434 | 231/18723 | 1.46e-05 | 3.71e-04 | 37 |
| GO:190305213 | Breast | IDC | positive regulation of proteolysis involved in cellular protein catabolic process | 25/1434 | 133/18723 | 2.34e-05 | 5.59e-04 | 25 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAGEF1 | deletion | Nonsense_Mutation | novel | c.627_631delNNNNN | p.Tyr209Ter | p.Y209* | Q9HAY2 | protein_coding | TCGA-CQ-5329-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MAGEF1 | deletion | Frame_Shift_Del | novel | c.168delN | p.Gly58AlafsTer19 | p.G58Afs*19 | Q9HAY2 | protein_coding | TCGA-CV-A461-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |